326
Participants
Start Date
November 26, 2020
Primary Completion Date
September 15, 2022
Study Completion Date
September 15, 2022
MenABCWY
Neisseria meningitis groups A, B, C W, and Y vaccine
Bivalent rLP2086 (60-µg Dose)
Trumenba (half dose) - Meningococcal Group B vaccine
Bivalent rLP2086 (120-µg Dose)
Trumenba - Meningococcal Group B vaccine
Bexsero
Bexsero - Meningococcal Group B vaccine
Prophylactic Liquid Paracetamol (PLP)
PLP administration during primary vaccinations 1 and 2
Nimenrix
Nimenrix - Meningococcal Group A, C, W and Y vaccine
Placebo
Normal Saline
Scheduled Liquid Paracetamol (SLP)
SLP administration after primary vaccinations 1 and 2.
Therapeutic Liquid Paracetamol (TLP)
TLP administration after primary vaccinations 1 and 2
P. & A. Kyriakou Children's Hospital, Athens
"University General Hospital ATTIKON", Athens
Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario Clinico San Carlos, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario HM Puerta del Sur, Móstoles
Grupo Pediatrico Uncibay, Málaga
Instituto Hispalense de Pediatria, Seville
Hospital Universitario Virgen Del Rocio, Seville
FISABIO, Valencia
Centro de Salud la Serreria II, Valencia
Centro de Salud Nazaret, Valencia
Centro de Salud L'Eliana, L'Eliana
Centro de Salud de Paiporta, Paiporta
"Ippokratio General Hospital of Thessaloniki", Thessaloniki
Dr. med Falko Panzer Praxis fuer Kinder und Jugendliche, Mannheim
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Universitario de Burgos, Burgos
Hospital Vithas Virgen del Mar, Almería
Lead Sponsor
Pfizer
INDUSTRY